Current role
Biotechnology · Healthcare
Board Member
2021-01-01–present
Andreas Krebs
Board Member
Definium Therapeutics, Inc. (DFTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DFTX alertsAbout Andreas Krebs
Andreas Krebs is recorded as Board Member at Definium Therapeutics, Inc. (DFTX) since January 1, 2021. The newest filing on record that lists Andreas Krebs as Board Member at Definium Therapeutics, Inc. (DFTX) is dated April 27, 2026. Definium Therapeutics, Inc. reported in an 8-K filed June 12, 2026 a re-election or new board role (Director) for Andreas Krebs, on the board since at least 2021, effective June 11, 2026. Definium Therapeutics, Inc. reported in an 8-K filed June 16, 2025 a re-election or new board role (member of the Board) for Andreas Krebs, on the board since at least 2021, effective June 12, 2025. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.
“The Company's seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the "2027 Annual Meeting") or until a successor has been duly elected or appointed, by the following votes:”
“The Company's six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Board until the 2026 annual general meeting of shareholders (the "2026 Annual Meeting") and until his or her successor is duly elected or qualified, by the following votes:”
Affiliation history
-
Current
2021-01-01–present
Last confirmed April 27, 2026
-
Definium Therapeutics, Inc. (DFTX)
Proxy statement
Start not stated–2022-04-18
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Definium Therapeutics, Inc.
- Dr. Roger Crystal CEO
- Dr. Suzanne Bruhn CEO
- JR Rahn CEO
- Robert Barrow CEO
- Stephen Hurst CEO
- Carol A. Vallone Chairman
- Brandi L. Roberts CFO
- David Gryska CFO
- Roger Adsett COO, Board Member
- Carrie F. Liao Chief Accounting Officer